Orthocell Ltd
OCC
Company Profile
Business description
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.
Contact
90 South Street
Building 191, Murdoch University
Murdoch
PerthWA6150
AUST: +61 893602888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,857.00 | 48.10 | 0.55% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 50,326.46 | 545.65 | -1.07% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,407.96 | 157.94 | -0.64% |
| NASDAQ | 25,418.76 | 260.06 | -1.01% |
| Nikkei 225 | 64,179.27 | 1,237.36 | -1.89% |
| NZX 50 Index | 13,253.65 | 49.57 | 0.38% |
| S&P 500 | 7,328.00 | 58.65 | -0.79% |
| S&P/ASX 200 | 8,653.30 | 61.90 | 0.72% |
| SSE Composite Index | 3,993.23 | 16.80 | -0.42% |